Novavax’s COVID vaccine shows long-term efficacy in UK trial
Published by Reuters UK (Reuters) – Novavax Inc said on Monday that an extended analysis of a late-stage study conducted in the United Kingdom showed that its COVID-19 vaccine provided long-term protection against the coronavirus. The protein-based vaccine, NVX-CoV2373, continued to provide protection and maintained overall efficacy of 82.7% over a six-month period, the company […]
Read More